Last reviewed · How we verify
ACS patients treated with OAP
OAP is an angiotensin receptor-neprilysin inhibitor.
OAP is an angiotensin receptor-neprilysin inhibitor. Used for Treatment of heart failure.
At a glance
| Generic name | ACS patients treated with OAP |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Angiotensin receptor-neprilysin inhibitor |
| Target | Angiotensin II receptor, Neprilysin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
OAP works by blocking the action of angiotensin II and neprilysin, leading to vasodilation and reduced blood pressure. This mechanism is thought to be beneficial in patients with heart failure.
Approved indications
- Treatment of heart failure
Common side effects
- Hyperkalemia
- Dizziness
- Headache
- Cough
- Nausea
Key clinical trials
- Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry
- REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets (OAP) in Patients With Acute Coronary Syndrome (ACS) in Be/Lux.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACS patients treated with OAP CI brief — competitive landscape report
- ACS patients treated with OAP updates RSS · CI watch RSS
- AstraZeneca portfolio CI